| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e50e5b30794eec28385dd579faf9c356 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761 |
| filingDate |
2020-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d12220f5422213ac06a818c0f8555cc |
| publicationDate |
2022-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022218845-A1 |
| titleOfInvention |
Virus and tumor therapeutic drug for specifically killing tumor cells |
| abstract |
Provided are a virus and a tumor therapeutic drug for specifically killing tumor cells. The virus is a recombinant oncolytic virus, and the genome thereof has an exogenous promoter inserted which is located upstream of an essential gene of the virus to replace the exogenous promoter of the essential gene, and to drive the expression of the essential gene in tumor cells but not in normal cells. The virus can kill a variety of tumor cells with an efficacy similar to that of the wild-type virus while it is safe to non-tumor cells. In vivo studies indicate that the oncolytic viruses provided in this disclosure can significantly inhibit tumor growth in various tumor animal models. |
| priorityDate |
2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |